Market Cap 58.79B
Revenue (ttm) 293.96B
Net Income (ttm) 1.51B
EPS (ttm) N/A
PE Ratio 19.61
Forward PE 19.05
Profit Margin 0.51%
Debt to Equity Ratio 3.73
Volume 1,706,500
Avg Vol 1,283,430
Day's Range N/A - N/A
Shares Out 193.88M
Stochastic %K 51%
Beta 0.58
Analysts Strong Sell
Price Target $336.21

Company Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management...

Industry: Medical Distribution
Sector: Healthcare
Phone: 610 727 7000
Address:
1 West First Avenue, Conshohocken, United States
farstriderr
farstriderr Aug. 13 at 3:28 PM
$COR many lawsuits coming from employees
1 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:00 PM
Wells Fargo has adjusted their stance on Cencora ( $COR ), setting the rating to Overweight with a target price of 337 → 354.
0 · Reply
Laynester
Laynester Aug. 12 at 2:39 PM
$CAH $COR BOOOOOO! Lowest [RSI] - and almost....almost....hit the trips. 1.44% and 0.77% dividend on each. That could be .....a good time to buy? Time will tell if the Money Flow returns.... [HOLDING]
0 · Reply
Laynester
Laynester Aug. 8 at 10:20 AM
$COR Has been terrible lately. That and [MCK] both....in fact the lowest on my long term chart RSI (ready for a turnaround??) in the portfolio here. Low RSI means BUY more - need a bit more sector news on that. BOOOOO - "Throw the bums out" - Don't hit my trip on the way out..... BOOOOO!!!!
0 · Reply
StockAutoPro
StockAutoPro Aug. 6 at 8:39 PM
$COR: Buy target $282.08 Sell target $298.28 Strong earnings report indicates potential growth for this leading biopharmaceutical company.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 6:11 PM
$COR beats Q3 earnings estimates — shares dip pre-market 🤔 Cencora reported an adjusted EPS of $4.00, beating the Zacks Consensus Estimate by 5.8% and showing a 19.8% growth in adjusted EPS year over year. Despite strong segment performance and updated FY25 guidance, shares were down 0.8% in pre-market trading. Full breakdown here 👉 https://www.zacks.com/stock/news/2673444/cor-q3-earnings-revenues-beat-estimates-25-eps-view-raised?cid=sm-stocktwits-2-2673444-body-6273&ADID=SYND_STOCKTWITS_TWEET_2_2673444_BODY_6273
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 1:49 PM
$COR just crushed Q3 — and raised FY25 guidance 💥 Earnings and revenues topped estimates, driven by strong growth in its U.S. segment. Find out what could drive the next leg higher 👉 https://www.zacks.com/stock/news/2673444/cor-q3-earnings-revenues-beat-estimates-25-eps-view-raised?cid=sm-stocktwits-2-2673444-teaser-6268&ADID=SYND_STOCKTWITS_TWEET_2_2673444_TEASER_6268
0 · Reply
kiwitc2000
kiwitc2000 Aug. 6 at 1:42 PM
$COR Earnings beat estimates, and than this happens?? All kinds of garbage runs this morning, but this solid company tanks. Time to add more?
0 · Reply
27R
27R Aug. 5 at 4:49 PM
$COR Earnings release before tomorrow's open. Significant post-earnings volatility expected, but implied vol remains reasonable. Straddle consideration?
0 · Reply
scientificway
scientificway Aug. 5 at 12:27 AM
$COR Loaded, MDXG, huge rev, eps, guidance up. , guidance is so good, how much after a year
0 · Reply
Latest News on COR
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript

Aug 6, 2025, 12:25 PM EDT - 16 days ago

Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript


Cencora Reports Fiscal 2025 Third Quarter Results

Aug 6, 2025, 6:30 AM EDT - 16 days ago

Cencora Reports Fiscal 2025 Third Quarter Results


Cencora Elects Lori J. Ryerkerk to Its Board of Directors

May 28, 2025, 7:30 AM EDT - 3 months ago

Cencora Elects Lori J. Ryerkerk to Its Board of Directors


Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

May 7, 2025, 10:55 AM EDT - 3 months ago

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript


Cencora Reports Fiscal 2025 Second Quarter Results

May 7, 2025, 6:30 AM EDT - 3 months ago

Cencora Reports Fiscal 2025 Second Quarter Results


3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

Apr 4, 2025, 3:42 PM EDT - 5 months ago

3 Nearly Trump-Proof Stocks Defying Trump's Tariff Shock

CVS MCK PM


Cencora: Higher Potential Returns After Reduced Walgreens Stake

Feb 26, 2025, 11:00 AM EST - 6 months ago

Cencora: Higher Potential Returns After Reduced Walgreens Stake


Cencora (COR) Q1 2025 Earnings Call Transcript

Feb 5, 2025, 11:40 AM EST - 7 months ago

Cencora (COR) Q1 2025 Earnings Call Transcript


Cencora raises 2025 profit forecast on specialty drug demand

Feb 5, 2025, 7:23 AM EST - 7 months ago

Cencora raises 2025 profit forecast on specialty drug demand


Cencora Reports Fiscal 2025 First Quarter Results

Feb 5, 2025, 6:30 AM EST - 7 months ago

Cencora Reports Fiscal 2025 First Quarter Results


Cencora raises annual profit forecast

Jan 2, 2025, 4:23 PM EST - 8 months ago

Cencora raises annual profit forecast


Cencora Completes Acquisition of Retina Consultants of America

Jan 2, 2025, 4:15 PM EST - 8 months ago

Cencora Completes Acquisition of Retina Consultants of America


Cencora Closes $1.8 Billion Senior Notes Offering

Dec 9, 2024, 4:15 PM EST - 9 months ago

Cencora Closes $1.8 Billion Senior Notes Offering


Cencora: Competitive Advantages Defined

Dec 5, 2024, 10:26 AM EST - 9 months ago

Cencora: Competitive Advantages Defined


Cencora to Host Inaugural Product Showcase

Nov 26, 2024, 8:30 AM EST - 9 months ago

Cencora to Host Inaugural Product Showcase


Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript

Nov 6, 2024, 10:56 AM EST - 10 months ago

Cencora, Inc. (COR) Q4 2024 Earnings Call Transcript


Cencora to buy Retina Consultants of America for $4.6 bln

Nov 6, 2024, 6:54 AM EST - 10 months ago

Cencora to buy Retina Consultants of America for $4.6 bln


Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Nov 6, 2024, 6:35 AM EST - 10 months ago

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results


Dividend Aristocrats Of The Future - Part 3

Nov 1, 2024, 4:42 PM EDT - 10 months ago

Dividend Aristocrats Of The Future - Part 3

AIZ COST CSX DUK K RSG SRE


Cencora Elects Frank Clyburn to Its Board of Directors

Aug 15, 2024, 7:30 AM EDT - 1 year ago

Cencora Elects Frank Clyburn to Its Board of Directors


Walgreens further reduces stake in Cencora

Aug 1, 2024, 6:20 PM EDT - 1 year ago

Walgreens further reduces stake in Cencora

WBA


Cencora says additional data stolen in February cyberattack

Jul 31, 2024, 6:14 PM EDT - 1 year ago

Cencora says additional data stolen in February cyberattack


Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript

Jul 31, 2024, 11:12 AM EDT - 1 year ago

Cencora, Inc. (COR) Q3 2024 Earnings Call Transcript


Cencora Reports Fiscal 2024 Third Quarter Results

Jul 31, 2024, 6:30 AM EDT - 1 year ago

Cencora Reports Fiscal 2024 Third Quarter Results


farstriderr
farstriderr Aug. 13 at 3:28 PM
$COR many lawsuits coming from employees
1 · Reply
JarvisFlow
JarvisFlow Aug. 13 at 1:00 PM
Wells Fargo has adjusted their stance on Cencora ( $COR ), setting the rating to Overweight with a target price of 337 → 354.
0 · Reply
Laynester
Laynester Aug. 12 at 2:39 PM
$CAH $COR BOOOOOO! Lowest [RSI] - and almost....almost....hit the trips. 1.44% and 0.77% dividend on each. That could be .....a good time to buy? Time will tell if the Money Flow returns.... [HOLDING]
0 · Reply
Laynester
Laynester Aug. 8 at 10:20 AM
$COR Has been terrible lately. That and [MCK] both....in fact the lowest on my long term chart RSI (ready for a turnaround??) in the portfolio here. Low RSI means BUY more - need a bit more sector news on that. BOOOOO - "Throw the bums out" - Don't hit my trip on the way out..... BOOOOO!!!!
0 · Reply
StockAutoPro
StockAutoPro Aug. 6 at 8:39 PM
$COR: Buy target $282.08 Sell target $298.28 Strong earnings report indicates potential growth for this leading biopharmaceutical company.
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 6:11 PM
$COR beats Q3 earnings estimates — shares dip pre-market 🤔 Cencora reported an adjusted EPS of $4.00, beating the Zacks Consensus Estimate by 5.8% and showing a 19.8% growth in adjusted EPS year over year. Despite strong segment performance and updated FY25 guidance, shares were down 0.8% in pre-market trading. Full breakdown here 👉 https://www.zacks.com/stock/news/2673444/cor-q3-earnings-revenues-beat-estimates-25-eps-view-raised?cid=sm-stocktwits-2-2673444-body-6273&ADID=SYND_STOCKTWITS_TWEET_2_2673444_BODY_6273
0 · Reply
ZacksResearch
ZacksResearch Aug. 6 at 1:49 PM
$COR just crushed Q3 — and raised FY25 guidance 💥 Earnings and revenues topped estimates, driven by strong growth in its U.S. segment. Find out what could drive the next leg higher 👉 https://www.zacks.com/stock/news/2673444/cor-q3-earnings-revenues-beat-estimates-25-eps-view-raised?cid=sm-stocktwits-2-2673444-teaser-6268&ADID=SYND_STOCKTWITS_TWEET_2_2673444_TEASER_6268
0 · Reply
kiwitc2000
kiwitc2000 Aug. 6 at 1:42 PM
$COR Earnings beat estimates, and than this happens?? All kinds of garbage runs this morning, but this solid company tanks. Time to add more?
0 · Reply
27R
27R Aug. 5 at 4:49 PM
$COR Earnings release before tomorrow's open. Significant post-earnings volatility expected, but implied vol remains reasonable. Straddle consideration?
0 · Reply
scientificway
scientificway Aug. 5 at 12:27 AM
$COR Loaded, MDXG, huge rev, eps, guidance up. , guidance is so good, how much after a year
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 5:03 PM
$COR earnings preview: Is the streak of surprises ending? 🚨 📊 Despite a strong U.S. Healthcare Solutions segment, Cencora's Earnings ESP is 0.00%, suggesting an earnings beat is unlikely this time. 🔍 Specialty volumes remain robust, but international segment weakness could weigh on results. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2663057/can-specialty-and-glp-1-momentum-support-cencoras-q3-results?cid=sm-stocktwits-2-2663057-body-5800&ADID=SYND_STOCKTWITS_TWEET_2_2663057_BODY_5800
0 · Reply
ZacksResearch
ZacksResearch Aug. 4 at 3:59 PM
$COR riding GLP-1 tailwinds — but will it be enough? 💊📉 Specialty and GLP-1 momentum is a clear driver, but international softness could weigh on Q3 results. Full breakdown here 👉 https://www.zacks.com/stock/news/2663057/can-specialty-and-glp-1-momentum-support-cencoras-q3-results?cid=sm-stocktwits-2-2663057-teaser-5741&ADID=SYND_STOCKTWITS_TWEET_2_2663057_TEASER_5741
0 · Reply
Osubuckeye134
Osubuckeye134 Jul. 31 at 6:44 PM
$CAH, $MCK, $COR it has to be understood, how big of an impact a pharma price reduction has on the big 3 distributors. The main drivers for revenue are: distribution fees & cash discounts, these are calculated as a percentage of revenue. Therefore if a drug is $1,000, lets just say they would normally make say $50. If the gov't pushes $LLY and others to reduce price, and the distributors now pay $500 for the same drug, they will then make $25. Same number of packages shipped, same number of invoices due from customers, same number of customer service calls...just a lower base of revenue. It's devastating to the business model, one that assumes inflation, not massive deflation overnight.
0 · Reply
NVDAMillionaire
NVDAMillionaire Jul. 30 at 4:14 PM
$COR Really good write-up that perfectly summarizes COR's present situation. So if you want to bring your COR knowledge up to date or just discover COR, this is required reading. https://beyondspx.com/article/cencora-s-specialty-ascent-fueling-growth-through-strategic-expansion-and-operational-edge-nyse-cor
0 · Reply
BucksNRoses
BucksNRoses Jul. 29 at 2:10 PM
$LTNC $COR info: https://finance.yahoo.com/news/ltncs-lockdin-partners-fortune-10-123000567.html
0 · Reply
JarvisFlow
JarvisFlow Jul. 16 at 1:00 PM
Morgan Stanley has adjusted their stance on Cencora ( $COR ), setting the rating to Equal-Weight with a target price of 313 → 330.
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 4:55 PM
$COR up 32.4% YTD — Can it keep the pace? 🚀 🔹 Strong U.S. Healthcare Solutions driving growth 🔹 Adjusted EPS projected to rise 14-16% in FY2025 🔹 Recent acquisition expands specialty capabilities Discover the full growth story here 👉 https://www.zacks.com/stock/news/2573188/heres-why-you-should-add-cencora-stock-to-your-portfolio-now?cid=sm-stocktwits-2-2573188-body-1317&ADID=SYND_STOCKTWITS_TWEET_2_2573188_BODY_1317
0 · Reply
ZacksResearch
ZacksResearch Jul. 11 at 12:44 PM
$COR is riding a strong growth wave — but is it enough? GLP-1 and specialty drug sales are fueling gains, making it a compelling pick now. But margin pressure and tough competition still loom large. See if the reward outweighs the risk 👉 https://www.zacks.com/stock/news/2573188/heres-why-you-should-add-cencora-stock-to-your-portfolio-now?cid=sm-stocktwits-0-2573188-teaser-1289&ADID=SYND_STOCKTWITS_TWEET_0_2573188_TEASER_1289
0 · Reply
Rayyleeee
Rayyleeee Jul. 10 at 9:43 PM
$CRWV $COR next catalyst should be their official announcement of a large-scale contract with Google this or next quarter...
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Jul. 3 at 8:07 PM
Cencora ($COR) expands receivables facility to $1.5B with enhanced accordion flexibility. While this boosts liquidity for pharma distribution ops, the debt-heavy balance sheet (7.76x D/E ratio) still looms large. Clever financial engineering or kicking the can? Market will decide. https://www.sec.gov/Archives/edgar/data/1140859/000110465925065769/tm2519648d1_8k.htm
0 · Reply
Estimize
Estimize Jul. 2 at 10:00 PM
Wall St is expecting 3.82 EPS for $COR Q3 [Reporting 07/30 BMO] http://www.estimize.com/intro/cor?chart=historical&metric_name=eps&utm_cont
0 · Reply
JarvisFlow
JarvisFlow Jun. 30 at 2:54 PM
Jefferies has adjusted their stance on Cencora ( $COR ), setting the rating to Hold with a target price of 275 → 300.
0 · Reply